Most Liquid Biotechnology Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1LSB LakeShore Biopharma Co,
201.56 M
 0.00 
 11.11 
 0.00 
2SYRE Spyre Therapeutics
198.34 M
 0.00 
 3.70 
 0.01 
3IMTXW immatics biotechnologies GmbH
178.39 M
(0.22)
 10.72 
(2.33)
4TRML Tourmaline Bio
147.76 M
 0.18 
 4.17 
 0.75 
5GRAL GRAIL, LLC
139.75 M
 0.11 
 3.81 
 0.41 
6LENZ LENZ Therapeutics
138.69 M
 0.18 
 4.65 
 0.85 
7GPCR Structure Therapeutics American
136.28 M
(0.03)
 4.24 
(0.11)
8MGX Metagenomi, Common Stock
133.59 M
(0.13)
 4.01 
(0.53)
9BRNS Barinthus Biotherapeutics plc
133.15 M
(0.06)
 5.91 
(0.33)
10BCAX Bicara Therapeutics Common
129.03 M
 0.07 
 5.92 
 0.44 
11AVBP ArriVent BioPharma, Common
128.72 M
 0.05 
 3.74 
 0.21 
12HUMAW Humacyte
127.9 M
(0.02)
 7.22 
(0.11)
13KRRO Frequency Therapeutics
120.47 M
 0.06 
 12.81 
 0.78 
14NGNE Neurogene
109.68 M
 0.01 
 11.65 
 0.16 
15APGE Apogee Therapeutics, Common
108.08 M
(0.04)
 3.47 
(0.16)
16ZURA Zura Bio Limited
104.8 M
(0.07)
 5.12 
(0.37)
17LXEO Lexeo Therapeutics, Common
100.11 M
(0.08)
 5.81 
(0.44)
18TSBX Turnstone Biologics Corp
16.91 M
(0.07)
 5.34 
(0.36)
19ATYR aTyr Pharma,
14.25 M
 0.22 
 4.81 
 1.08 
20CRVO CervoMed
13.8 M
(0.17)
 5.56 
(0.97)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).